This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Complete regressions of skin tumors following topical applications of anticancer drugs were reported to the American Association for Cancer Research in Philadelphia.
There was minimal toxicity to adjacent normal structures, and some of the tumors have not reappeared for as long as three years, said Edmund Klein, MD, chief of dermatology, Roswell Park Memorial Institute.
Co-investigators are Halina Milgrom, MD, H. L. Traenkle, MD, H. L. Stoll, MD, Yona Laor, MD, Ronald S. Nadel, MD, and Robert Case, BS.
The study of several antitumor agents in varying strengths encompassed more than 500 primary skin lesions in about 100 patients and secondary neoplasms in approximately 25 patients with more than 100 lesions.
The study was designed as a method of investigating the chemotherapeutic effects of antitumor agents in large concentrations without the risk of toxicity that would result from systemic use. In patients with multiple cancers, such a system also provides
Anticancer Drugs Applied Topically for Skin Tumors. JAMA. 1965;192(6):30–36. doi:10.1001/jama.1965.03080190162056
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: